Tracking how labeled glucose is used by immune cells in real time
Tracing Of Real-time glu13Cose Metabolism in Human Immune Cells
NA · Vanderbilt University Medical Center · NCT06930976
Adults will receive a short infusion of safe, non-radioactive labeled glucose while researchers take blood immune cells to see how those cells use glucose for energy and as building material.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 12 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Vanderbilt University Medical Center (other) |
| Locations | 1 site (Nashville, Tennessee) |
| Trial ID | NCT06930976 on ClinicalTrials.gov |
What this trial studies
This single-site interventional study gives participants an intravenous infusion of 13C6-glucose, a non-radioactive stable isotope tracer, over a few hours. Investigators will collect blood samples during and after the infusion to isolate immune cell populations and measure incorporation of the 13C label into metabolic pathways using mass spectrometry and tracer analysis. The goal is to map real-time glucose uptake and its use for energy production and biosynthesis within human immune cells. Standard exclusions include pregnancy, uncontrolled diabetes, incarceration, recent large blood draws, or any condition or medication judged by investigators to interfere with the measurements.
Who should consider this trial
Good fit: Adults age 18 or older who can attend in-person visits at Vanderbilt, are not pregnant, do not have uncontrolled diabetes, and can safely provide the required blood samples are ideal candidates.
Not a fit: People who are pregnant, incarcerated, have uncontrolled hyperglycemia/diabetes, or have medical conditions or medications that could interfere with metabolism are unlikely to benefit and are excluded.
Why it matters
Potential benefit: If successful, the work could reveal how immune cells alter glucose use and guide development of better diagnostics or therapies for immune-related conditions.
How similar studies have performed: Stable isotope tracer approaches like 13C-glucose have been used successfully in animal models and human metabolic studies, but applying real-time 13C tracing specifically to circulating immune cells is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged 18 or older Exclusion Criteria: * Pregnant * Prisoner or in police custody * Uncontrolled hyperglycemia/diabetes * Current participation in another study where the total volume of blood drawn, when added to this study blood draw volume, exceeds 500cc in an 8 week period * Any medical issue or pharmacologic exposure which, in the opinion of the study investigator, that might interfere with the study objectives * Any reason which, in the opinion of the study investigator, adds additional risk to the participant
Where this trial is running
Nashville, Tennessee
- Vanderbilt University Medical Center — Nashville, Tennessee, United States (RECRUITING)
Study contacts
- Principal investigator: Matthew T Stier, M.D., Ph.D. — Vanderbilt University Medical Center
- Study coordinator: Matthew T Stier, M.D., Ph.D.
- Email: matthew.stier@vumc.org
- Phone: 615-875-4978
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Glucose, Metabolism, Isotope Labeling, Immune System and Related Disorders